Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 26, 2025
Daily News
May 26, 2025
- Sun Pharma Japan Eyes 10%-Plus CAGR as It Pivots to New Drug Biz
May 26, 2025
- Santen Aims to Net 400 Billion Yen in FY2029 Riding on Myopia, Droopy Eyelid Drugs
May 26, 2025
- Novartis Keen to Ensure Stable Supply of Radioligand Therapies in Japan
May 26, 2025
- Pfizer Files Anaemetro’s Pediatric Use; Coverage Already Granted
May 26, 2025
- MSD’s Welireg, BMS’ Inrebic, J&J’s Talvey Up for Japan Panel Review on June 6
May 26, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…